Fulvestrant
Back to searchMolecule Structure
Scientific Name
Fulvestrant
Description of the Drug
Fulvestrant is an estrogen receptor antagonist used to treat HR+ breast cancer that may also be HER2-.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00947
http://www.drugbank.ca/drugs/DB00947
Brand Name(s)
Faslodex
Company Owner(s)
Apotex Inc, Fresenius Kabi Usa Llc, Teva Pharmaceuticals Usa Inc, Sagent Pharmaceuticals Inc, Astrazeneca Pharmaceuticals Lp, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Sandoz Inc, Glenmark Pharmaceuticals Inc Usa, Xiromed Pharma Espana Sl, Accord Healthcare Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Estrogen receptor | PROTEIN FAMILY | ANTAGONIST | CHEMBL2093866 |
Clinical Trial(s)
Unichem Links
| Atlas | fulvestrant | |
| SureChEMBL | SCHEMBL8209 | |
| PharmGKB | PA164747170 | |
| DrugBank | DB00947 | |
| PubChem: Thomson Pharma | 14911923 | 14887338 |
| PubChem | 104741 | |
| LINCS | LSM-6504 | |
| Nikkaji | J401.163E | |
| BindingDB | 50238741 | 50169743 |
| EPA CompTox Dashboard | DTXSID4022369 | |
| DrugCentral | 1255 | |
| ChemicalBook | CB0698542 | |
| Guide to Pharmacology | 1015 | |
| rxnorm | FULVESTRANT | FASLODEX |
| PubChem: Drugs of the Future | 12014659 | |
| ChEBI | 31638 |
